Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia

BMC Psychiatry

Sukhwinder S. Shergill¹  Maria-Jesus Mateos Fernandez²  S. Neil Sarkar³  Dan W. Joyce¹  Derek K. Tracy² 

[1] South London and Maudsley NHS Foundation Trust, London, UK;Cognition, Schizophrenia & Imaging Laboratory, Department of Psychosis Studies, the Institute of Psychiatry, King’s College London, London, UK;Central and North West London NHS Foundation Trust, London, UK

关键词: Treatment;    Refractory;    Psychosis;    Schizophrenia;   

Others  :  1225010
DOI  :  10.1186/s12888-015-0559-x

 received in 2014-10-30, accepted in 2015-07-14,  发布年份 2015

【 摘 要 】

Background

Clozapine is the treatment of choice for medication refractory psychosis, but it does not benefit half of those put on it. There are numerous studies of potential post-clozapine strategies, but little data to guide the order of such treatment in this common clinical challenge. We describe a naturalistic observational study in 153 patients treated by a specialist psychosis service to identify optimal pharmacotherapy practice, based on outcomes.

Methods

Medication and clinical data, based on the OPCRIT tool, were examined on admission and discharge from the national psychosis service. The primary outcome measure was the percentage change in mental state examination symptoms between admission and discharge and the association with medication on discharge. Exploratory analyses evaluated the specificity of individual medication effects on symptom clusters.

Results

There were fewer drugs prescribed at discharge relative to admission, suggesting an optimisation of medication, and a doubling of the number of patients treated with clozapine. Treatment with clozapine on discharge was associated with maximal decrease in symptoms from admission. In the group of patients that did not respond to clozapine monotherapy, the most effective drug combinations were clozapine augmentation with 1) sodium valproate, 2) lithium, 3) amisulpride, and 4) quetiapine. There was no support for a dose–response relationship for any drug combination.

Conclusions

Clozapine monotherapy is clearly the optimal medication in medication refractory schizophrenia and it is possible to maximise its use. In patients unresponsive to clozapine monotherapy, augmentation with sodium valproate, lithium, amisulpride and quetiapine, in that order, is a reasonable treatment algorithm. Reducing the number of ineffective drugs is possible without a detrimental effect on symptoms. Exploratory data indicated that clozapine was beneficial across a range of symptoms domains, whereas olanzapine was beneficial specifically for hallucinations and lamotrigine for comorbid affective symptoms.

【 授权许可】

   
2015 Tracy et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013, 14(1):2-44.
• [2]Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al.: A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013, 39(6):1296-306.
• [3]Rowe AR, Mercer L, Casetti V, Sendt K-V, Giaroli G, Shergill SS, et al.: Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia. J Psychopharmacol 2015, 29(2):197-211.
• [4]Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al.: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382(9896):951-62.
• [5]Chakos M, Lieberman J, Hoffman E, Bradford D, Schumann G: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001, 158(4):518-26.
• [6]Essali A, Al-Haj Haasan N, Li C, Rathbone J: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009, 1:CD000059.
• [7]Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al.: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001, 58(10):965-72.
• [8]Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al.: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994, 151(12):1744-52.
• [9]Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Singh B, et al.: World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008, 100(1–3):20-38.
• [10]Taylor DM, Smith L, Gee SH, Nielsen J: Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 2012, 125(1):15-24.
• [11]Tracy DK, Sendt K-V, Shergill SS: Antipsychotic polypharmacy: still dirty, but hardly a secret. A systematic review and clinical guide. Current Psychopharmacology 2013, 2(2):143-171.
• [12]Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012, 13(5):318-78.
• [13]NICE, Core interventions in the treatment and management of schizophrenia in primary and secondary care (update), 2009, London, UK: National Institute for Health and Care Excellence.
• [14]Taylor D, Paton C, Kapur S. Prescribing Guidelines in Psychiatry. 11 ed, ed. D. Taylor, C. Paton, and S. Kapur. 2012, London, UK: Wiley-Blackwell
• [15]Tracy DK, Shergill SS: Treatment-Refractory Schizophrenia: definition and assessment. In Treatment Refractory Schizophrenia: a clinical conundrum. Edited by Gaughran F, Buckley PF. Springer, Berlin; 2014.
• [16]Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, et al.: Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001, 178:506-17.
• [17]Warnez S, Alessi-Severini S: Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014, 14:102. BioMed Central Full Text
• [18]Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP: The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry 2012, 73(4):498-503.
• [19]DoH, NHS Specialised Services: Definition no 22. Specialised mental health services (all ages). D.o. Health, London, UK; 2009.
• [20]Sarkar SN, Tracy DK, Fernandez M-JM, Nalesnik N, Dhillon G, Onwumere J, et al. Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. The Psychiatric Bulletin, 2014; 38:71-74.
• [21]Brittain PJ, Stahl D, Rucker J, Kawadler J, Schumann G: A review of the reliability and validity of OPCRIT in relation to its use for the routine clinical assessment of mental health patients. Int J Methods Psychiatr Res 2013, 22(2):110-37.
• [22]McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991, 48(8):764-70.
• [23]Pagel T, Baldessarini RJ, Franklin J, Baethge C: Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder. Bipolar Disord 2013, 15(3):229-39.
• [24]Tukey JW. Exploratory Data Analysis. 1977, New York, USA: Pearson.
• [25]Mihalopoulos C, McGorry P, Roberts S, McFarlane C: The procedural validity of retrospective case note diagnosis. Aust N Z J Psychiatry 2000, 34(1):154-9.
• [26]Sendt KV, Tracy DK, Bhattacharyya S: A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res 2015, 225(1–2):14-30.
• [27]Howes OD, Verqunst F, Gee S, McGuire P, Kapur S, Taylor D: Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012, 201(6):481-485.